GlassScriptPhysician profile
Shirley K Gibson
NPI 1770509713
$2,160.74
in general payments reported to CMS, 2019-2025
30 companies · $293 in 2025
The $293 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $192 · 2020: $264 · 2021: $369 · 2022: $366 · 2023: $415 · 2024: $261 · 2025: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $969.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $968.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $356.12 | 2021-2025 | Vraylar, Linzess, Creon |
| Lilly USA, LLC | $291.12 | 2020-2025 | Mounjaro, Trulicity, Zepbound |
| Astrazeneca Pharmaceuticals LP | $223.62 | 2019-2025 | Farxiga, Breztri, Flumist Quadrivalent |
| Pfizer INC. | $186.94 | 2019-2025 | |
| Glaxosmithkline, LLC. | $129.12 | 2019-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Allergan, INC. | $108.16 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.48 | 2020-2024 | Jardiance |
| Novo Nordisk INC | $76.21 | 2019-2023 | Ozempic, Rybelsus |
| Amgen INC. | $63.20 | 2022-2023 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $58.64 | 2022 | |
| Sanofi-Aventis U.S. LLC | $56.62 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $46.61 | 2022-2023 | |
| Exact Sciences Corporation | $43.18 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $40.40 | 2019-2024 | Gardasil 9, Vaxelis, Gardasil |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39.86 | 2025 | Caplyta |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $37.26 | 2024-2025 | Gvoke Hypopen |
| Janssen Pharmaceuticals, INC | $30.80 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $28.94 | 2025 | Fanapt |
| Gilead Sciences, INC. | $26.82 | 2024 | |
| Genentech USA, INC. | $26.09 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $25.85 | 2021 | |
| Sobi, INC | $23.89 | 2022 | |
| Supernus Pharmaceuticals, INC. | $21.06 | 2019 | |
| Axsome Therapeutics, INC. | $18.58 | 2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.45 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.75 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $16.54 | 2025 | Rexulti |
| Sanofi Pasteur INC. | $15.84 | 2023 | |
| Phathom Pharmaceuticals, INC. | $15.27 | 2024 | Voquezna |
| Mylan Specialty L.P. | $12.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shirley Gibson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.